The kinase Fyn as a novel intermediate in L-DOPA induced dyskinesia in Parkinson's disease

SANS-BLASCO SARA; SABORIDO MARIANO; AVALE, MARIA ELENA; DAMIANICH ANA; TARAVINI IRENE; JUAN E FERRARIO; BORDONE MELINA; BERNARDI ALEJANDRA; OSCAR GERSHANIK

MOLECULAR NEUROBIOLOGY

HUMANA PRESS INC

Lugar: Totowa, NJ; Año: 2018 vol. 55 p. 5125 - 5137

0893-7648

Dopamine replacement therapy with L-DOPA is the treatment of choice for Parkinson?s disease, however, its long-term use is frequently associated with L-DOPA-induced dyskinesia (LID). Many different molecules have been implicated in the development of LID and several of these have been proposed as potential therapeutic targets. However, to date none of these molecules have demonstrated full clinical efficacy, either because they lie downstream of dopaminergic signaling, or due to adverse side effects. Therefore, discovering new strategies to reduce LID in Parkinson?s disease remains a major challenge.Here we have explored the tyrosine kinase Fyn, as a novel intermediate molecule in the development of LID. Fyn, a member of the Src kinase family, is located in the post synaptic density, where it regulates phosphorylation of the NR2B subunit of the NMDA receptor in response to dopamine D1 receptor stimulation. We have used Fyn knockout and wild-type mice, lesioned with 6-hydroxydopamine and chronically treated with L-DOPA, to investigate the role of Fyn in the induction of LID. We found that mice lacking Fyn displayed reduced LID, ΔFosB accumulation and NR2B phosphorylation compared to wild-type control mice. Pre-administration of saracatinib (AZD0530), an inhibitor of Fyn activity, also significantly reduced LID in dyskinetic wild-type mice. These results support that Fyn has a critical role in the molecular pathways affected during the development of LID and identify Fyn as a novel potentially therapeutic target for the management of dyskinesia in Parkinson?s disease.